Group items tagged

NHS England has expanded its national bowel screening programme to people aged 54 so that cancers can be detected at an earlier stage when they are easier to treat. As part of the expansion, the health service would be sending a home-testing kit for bowel cancer, known as the Faecal Immunochemical Test (FIT), to thousands more people in the North West. Those who are eligible (aged 54 and over) will now automatically receive the kit every two years by post, enabling them to self-check for blood in stool samples, which can be a sign of bowel cancer. With the expansion of the NHS Bowel Cancer Screening Programme to people aged 54 years, an additional 830,000 people in England will now be eligible for the screening test.

Thousands of cancer patients in England are set to gain fast-tracked access to personalised cancer vaccine trials through a new National Health Service(NHS) initiative, the Cancer Vaccine Launch Pad. This groundbreaking service aims to find new life-saving treatments by matching eligible patients with clinical trials across the country. The first patient to receive a personalised vaccine for bowel cancer is Elliot Phebve, a 55-year-old lecturer, treated at University Hospitals Birmingham NHS Foundation Trust. Phebve, diagnosed through a routine health check, underwent surgery and chemotherapy before joining the trial. Sponsored by German biotech company BioNTech SE, the colorectal cancer vaccine trial is one of several taking place across NHS trusts.

The new test, which involves the quick removal of growths with the potential to turn cancerous, has been devised following a 16-year-old study, 'The Lancet' reported. The study of more than 170,000 volunteers aged between 55 and 64 suggested that the examination of the lower colon and rectum reduced deaths by 43 per cent.

The NHS claims that it's been able to save taxpayers £1.2 billion in just three years by procuring hundreds of hospital medicines at a better price. The adoption of cheaper versions of a single drug - adalimumab - which is used to treat more than 45,000 patients with rheumatoid arthritis, inflammatory bowel disease and psoriasis, has accounted for about one third of the savings. After the exclusive patent on the drug - originally known as its brand name Humira - expired in 2018, the NHS struck cost-saving deals to bulk-buy generic versions, which have the same quality, safety and efficacy of a branded one. Since then, tens of millions of pounds have been saved by buying cheaper generic versions of other medicines for conditions ranging from severe skin infections to aggressive blood cancers. Four in five medicines prescribed in the NHS are now non-branded, helping the NHS to achieve significant savings while ensuring the continuity of high-quality patient care. NHS chief executive Amanda Pritchard said: "Smart deals by the NHS mean patients are getting the best medicines and taxpayers are getting best value.